A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)

2013696 citationsJournal Articlebronze Open Access

Authors

NB represents a novel pharmacological approach to the treatment of obesity, and may become a valuable new therapeutic option.

Good health and well-being

Published in: Obesity

Volume 21, Issue 5, pp. 935-943

Field-Weighted Citation Impact: 43.56